Literature DB >> 29570868

Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study.

Kasia A Sablik1, Marian C Clahsen-van Groningen2, Caspar W N Looman3, Jeffrey Damman2, Dave L Roelen4, Madelon van Agteren1, Michiel G H Betjes1.   

Abstract

Chronic-active antibody-mediated rejection (c-aABMR) is defined as histological evidence of chronic endothelial injury (cg), also known as transplant glomerulopathy, and either microvascular inflammation (MVI) or positivity for C4d. Importantly, the presence of donor-specific antibodies (DSA) is currently still mandatory for the diagnosis of c-aABMR. This retrospective study of 41 c-aABMR patients investigates whether cases suspicious for c-aABMR (DSA negative, n = 24) differ from cases of c-aABMR (DSA positive, n = 17) with respect to renal histology, allograft function and long-term graft survival. All included patients had progressive loss of allograft function and were diagnosed by for cause biopsy and scored according to the Banff '15 criteria. In all DSApos cases, DSA were de novo and the majority was directed against HLA-II being mostly anti-HLA-DQ antibodies. There were no statistically significant differences in clinical characteristics, decline in allograft function and renal allograft survival in cases with or without DSAs. All cases showed chronic histomorphological damage and inflammation, irrespective of the presence of DSA. Renal histology and clinical outcome of patients suspicious for c-aABMR (DSAneg) do not significantly differ from patients with a diagnosis of c-aABMR (DSApos). We believe that our study adds to the ongoing debate regarding the need for DSAs to be present for the diagnosis of c-aABMR.
© 2018 Steunstichting ESOT.

Entities:  

Keywords:  HLA-antibody posttransplantation; histocompatibility and immunogenetics; kidney clinical; rejection

Mesh:

Substances:

Year:  2018        PMID: 29570868     DOI: 10.1111/tri.13154

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  10 in total

1.  Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.

Authors:  Candice Roufosse; Jan Ulrich Becker; Marion Rabant; Daniel Seron; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

2.  Association between transplant glomerulopathy and graft outcomes following kidney transplantation: A meta-analysis.

Authors:  Gábor Kovács; Giovanna Devercelli; Tamás Zelei; Ishan Hirji; Zoltán Vokó; Paul A Keown
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

3.  The FCGR3A 158 V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection.

Authors:  Nicolle Litjens; Annemiek Peeters; Judith Kal-van Gestel; Mariska Klepper; Michiel Betjes
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

4.  Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.

Authors:  Marius Andreas Koslik; Justa Friebus-Kardash; Falko Markus Heinemann; Andreas Kribben; Jan Hinrich Bräsen; Ute Eisenberger
Journal:  Front Med (Lausanne)       Date:  2022-01-31

Review 5.  Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms.

Authors:  Emilie Lebraud; Maëva Eloudzeri; Marion Rabant; Baptiste Lamarthée; Dany Anglicheau
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

6.  Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.

Authors:  Gastón J Piñeiro; Erika De Sousa-Amorim; Manel Solé; José Ríos; Miguel Lozano; Frederic Cofán; Pedro Ventura-Aguiar; David Cucchiari; Ignacio Revuelta; Joan Cid; Eduard Palou; Josep M Campistol; Federico Oppenheimer; Jordi Rovira; Fritz Diekmann
Journal:  BMC Nephrol       Date:  2018-10-11       Impact factor: 2.388

Review 7.  The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage.

Authors:  Tsukasa Nakamura; Takayuki Shirouzu; Katsuya Nakata; Norio Yoshimura; Hidetaka Ushigome
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

8.  The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.

Authors:  Alexandre Loupy; Mark Haas; Candice Roufosse; Maarten Naesens; Benjamin Adam; Marjan Afrouzian; Enver Akalin; Nada Alachkar; Serena Bagnasco; Jan U Becker; Lynn D Cornell; Marian C Clahsen-van Groningen; Anthony J Demetris; Duska Dragun; Jean-Paul Duong van Huyen; Alton B Farris; Agnes B Fogo; Ian W Gibson; Denis Glotz; Juliette Gueguen; Zeljko Kikic; Nicolas Kozakowski; Edward Kraus; Carmen Lefaucheur; Helen Liapis; Roslyn B Mannon; Robert A Montgomery; Brian J Nankivell; Volker Nickeleit; Peter Nickerson; Marion Rabant; Lorraine Racusen; Parmjeet Randhawa; Blaise Robin; Ivy A Rosales; Ruth Sapir-Pichhadze; Carrie A Schinstock; Daniel Seron; Harsharan K Singh; Rex N Smith; Mark D Stegall; Adriana Zeevi; Kim Solez; Robert B Colvin; Michael Mengel
Journal:  Am J Transplant       Date:  2020-05-28       Impact factor: 8.086

9.  Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection.

Authors:  Marta Crespo; Laura Llinàs-Mallol; Dolores Redondo-Pachón; Carrie Butler; Javier Gimeno; María José Pérez-Sáez; Carla Burballa; Anna Buxeda; Carlos Arias-Cabrales; Montserrat Folgueiras; Sara Sanz-Ureña; Nicole M Valenzuela; Elaine F Reed; Julio Pascual
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 8.786

10.  The causes and frequency of kidney allograft failure in a low-resource setting: observational data from Iraqi Kurdistan.

Authors:  Alaa Abbas Ali; Safaa E Almukhtar; Kais H Abd; Zana Sidiq M Saleem; Dana A Sharif; Michael D Hughson
Journal:  BMC Nephrol       Date:  2021-08-07       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.